Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Most high-level statements about indications, PPI class, formulation, and some common adverse reactions align with the supplied label excerpts, but several statements are unsupported or go beyond the label (e.g., irreversible mechanism details, manufacturer/patent/generic claims, enantiomer/specific stereoisomer claims, and prolonged acid suppression comparison). Missing material safety elements such as boxed warnings/major warnings are not addressed.
Category Scores
Accurate Statements
Dexlansoprazole is a proton pump inhibitor (PPI) used for treating gastroesophageal reflux disease (GERD) and related conditions.
Label excerpts provided include GERD-related indications (EE healing/maintenance and symptomatic non-erosive GERD heartburn).
Dexlansoprazole is available in extended-release capsules.
Product is described as delayed-release capsules in the label excerpts; the claim is consistent in general but uses different wording (see unsupported note).
Dexlansoprazole is prescribed for healing erosive esophagitis.
Indication: healing of all grades of erosive esophagitis (EE) for up to eight weeks.
Dexlansoprazole is prescribed for maintaining healing of erosive esophagitis.
Indication: maintain healing of EE and relief of heartburn for up to six months in adults and 16 weeks in patients 12 to 17 years of age.
Dexlansoprazole is prescribed for managing heartburn associated with GERD.
Indications include relief of heartburn with EE maintenance and symptomatic non-erosive GERD for four weeks.
Dexlansoprazole decreases the amount of acid produced by the stomach.
Wording is consistent with label excerpts describing PPI effect on reducing gastric acidity (implied by CgA increase secondary to PPI-induced decreases in gastric acidity).
Common side effects of dexlansoprazole include diarrhea, nausea, headache, and abdominal pain.
Label excerpt lists common adverse reactions (diarrhea, abdominal pain, nausea). Headache is not included in the provided “common adverse reactions” excerpt, so this part is only partially supported.
Omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole are PPIs.
No label excerpt provided explicitly listing these agents; therefore only class-related statements are considered broadly consistent but this specific list is not supported by the supplied excerpts.
Dexlansoprazole is formulated with dual delayed-release technology.
Clinical pharmacology excerpt: “dual delayed-release formulation.”
Dual delayed-release technology allows for two distinct pH-dependent releases of dexlansoprazole in the gastrointestinal tract.
Clinical pharmacology excerpt references two distinct peaks resulting from dual delayed-release formulation; pH-dependent release wording is not explicitly shown in the provided excerpt.
Dexlansoprazole is marketed under the brand name Dexilant.
No label excerpt provided explicitly states the brand name.
Unsupported Statements
Dexlansoprazole is available in extended-release capsules.
Label excerpt specifies “delayed-release capsules,” not “extended-release.”
Dexlansoprazole irreversibly blocks the H+/K+-ATPase enzyme system in gastric parietal cells.
No such mechanistic detail (irreversible H+/K+-ATPase blockade) appears in the supplied label excerpts.
Common side effects of dexlansoprazole include diarrhea, nausea, headache, and abdominal pain.
Label excerpt lists diarrhea, abdominal pain, and nausea as common adverse reactions; headache is not included in the provided “Common adverse reactions (adults, ≥2%)” excerpt.
Omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole are PPIs.
No label excerpt provided explicitly enumerates these PPIs.
PPI medications share a similar mechanism of action in reducing stomach acid.
No explicit statement in the supplied label excerpts describing shared mechanism beyond dexlansoprazole-related gastric acidity reduction.
The price of dexlansoprazole can vary based on dosage, quantity, insurance coverage, and the pharmacy chosen.
Not present in the supplied label excerpts.
Generic options, when available, typically offer a lower price point compared to brand-name versions.
Not present in the supplied label excerpts.
Takeda Pharmaceuticals is the original manufacturer of dexlansoprazole.
Not present in the supplied label excerpts.
Dexlansoprazole is marketed under the brand name Dexilant.
Brand name not included in the supplied label excerpts.
Following patent expirations, other pharmaceutical companies may produce and market generic versions of dexlansoprazole.
Not present in the supplied label excerpts.
Dexlansoprazole is an enantiomer of lansoprazole.
No stereochemical relationship is provided in the supplied label excerpts.
Dexlansoprazole is a specific stereoisomer of lansoprazole.
No stereochemical relationship is provided in the supplied label excerpts.
Dual delayed-release technology allows for two distinct pH-dependent releases of dexlansoprazole in the gastrointestinal tract.
The label excerpt provided indicates two distinct peaks but does not explicitly state “pH-dependent releases.”
The dual delayed-release formulation is designed to provide prolonged acid suppression compared to some other PPIs.
No such comparative efficacy/suppression duration statement appears in the supplied label excerpts.
Contradictions
Important Omissions
Key contraindications and interaction contraindication (e.g., contraindication with rilpivirine-containing products; avoidance with nelfinavir) are not mentioned.
Importance:
High
Major warnings/precautions are not addressed (e.g., acute tubulointerstitial nephritis, C. difficile-associated diarrhea, severe cutaneous adverse reactions, lupus syndromes, cyanocobalamin deficiency, hypomagnesemia, fundic gland polyps, and guidance about lowest dose/shortest duration).
Importance:
High
No dosing regimen details are provided (e.g., specific 60 mg for EE healing up to 8 weeks, 30 mg for maintenance/relief up to 6 months in adults and 16 weeks in ages 12–17, and 30 mg for symptomatic non-erosive GERD for 4 weeks).
Importance:
Moderate
Administration instructions are not mentioned (e.g., swallow whole; do not chew; missed dose instructions; applesauce/NG tube options).
Importance:
Moderate
Specific pediatric usage boundaries are not mentioned (e.g., not established for <12 years; not recommended in <2 years; effectiveness not shown for some younger age ranges).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several clinically important label elements (contraindications, major warnings/precautions, and specific dosing/administration) are omitted, and some mechanistic/technical claims are unsupported; this reduces labeling fidelity and could lead to incomplete safety communication.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Multiple unsupported or out-of-scope claims (mechanism irreversibility, stereochemistry, brand/manufacturer/price/generic assertions, comparative prolonged suppression) and material omissions of contraindications, warnings/precautions, dosing regimen, and administration instructions.
Suggested Improvement
Limit claims to what is explicitly supported by the label excerpts provided: use “delayed-release” wording, remove unsupported stereochemistry/manufacturer/price statements, avoid mechanistic details not shown, and include label-supported dosing regimens plus major contraindications and warnings/precautions. Add administration instructions if making use claims.